$PFE · Pfizer Inc.
Pfizer Inc. filed a Form 13F with the Securities and Exchange Commission on November 12, 2026, disclosing its holdings of publicly traded equity securities for the reporting period. The filing lists investments in a range of biotechnology and pharmaceutical companies, with share counts and market values for each position.
The largest reported positions by value include Allogene Therapeutics at approximately $36.4 million, Arvinas at approximately $26.2 million, Celcuity at approximately $23.5 million, Agomab Therapeutics at approximately $22.6 million, and Pyxis Oncology, which has combined sole and delegated positions totaling roughly $20.1 million. Other holdings include Biohaven, Cardiff Oncology, Caribou Biosciences, Ginkgo Bioworks, NextCure, ORIC Pharmaceuticals, Senseonics, Spero Therapeutics, Wave Life Sciences, Zentalis Pharmaceuticals, and Zura Bio.
The filing distinguishes between shares reported as SOLE, meaning Pfizer has sole investment discretion over those positions, and DFND, meaning investment discretion has been delegated. The filing itself provides only the security names, share counts, and values, and does not include commentary on the reasons for the positions or any changes during the period.